1. Home
  2. ASMB vs APLT Comparison

ASMB vs APLT Comparison

Compare ASMB & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$36.00

Market Cap

553.6M

Sector

Health Care

ML Signal

HOLD

Logo Applied Therapeutics Inc.

APLT

Applied Therapeutics Inc.

HOLD

Current Price

$0.12

Market Cap

38.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASMB
APLT
Founded
2005
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
553.6M
38.1M
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
ASMB
APLT
Price
$36.00
$0.12
Analyst Decision
Strong Buy
Hold
Analyst Count
6
3
Target Price
$43.40
$1.25
AVG Volume (30 Days)
124.4K
27.2M
Earning Date
11-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$37,191,000.00
$1,000,000.00
Revenue This Year
$42.01
$124.18
Revenue Next Year
N/A
$66.67
P/E Ratio
N/A
N/A
Revenue Growth
31.30
N/A
52 Week Low
$7.75
$0.11
52 Week High
$39.71
$1.50

Technical Indicators

Market Signals
Indicator
ASMB
APLT
Relative Strength Index (RSI) 57.82 25.40
Support Level $35.05 $0.21
Resistance Level $38.82 $0.26
Average True Range (ATR) 1.91 0.02
MACD -0.32 0.02
Stochastic Oscillator 42.70 5.13

Price Performance

Historical Comparison
ASMB
APLT

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Share on Social Networks: